RE:RE:RE:Waiting mode... I also think the pandemic has paradoxically, but positively, changed the approach to biotech valuations. Despite the early pessimism & macroeconomic impact the pandemic had on many sectors, the biotech sector continued to flourish with record interest/investment over the past 2 years.
Society & many of its institutions seem to be undergoing a major shift in priorities & the "business as usual" culture...& I don't see this changing. With greater emphasis now being placed on health, safety, family & overall quality of life, there should be one positive coming from this pandemic, & that is greater attention/value being placed on the core of such a shift = promising biotech. No one will be excluded from this shift imo, which includes not only patients, families & docs, but also governments, agencies (I.e. FDA) & Big Pharma. My guess is traditional biotech valuations are rapidly evolving de facto & future valuations will better reflect this general shift in values. The only question in my mind is...will promising biotech be able to meet growing demand. All JMO. Good luck...